IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,32 -0,71 (-0,86%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
59.293,02 +190,60 (+0,32%)
ProKidney Corp. (PROK)
Después del cierre:
ProKidney Corp.
2000 Frontis Plaza Blvd.
Suite 250
Winston-Salem, NC 27103
United States
336 999 7028
https://www.prokidney.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 163
Descripción
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Gobierno corporativo
El ISS Governance QualityScore de ProKidney Corp., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 10; Tablero: 7; Derechos de los accionistas: 4; Compensación: 7.
